NCT05807776

Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.

A Phase II Prospective Study to Evaluate the Safety and Efficacy of Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Tianjin Medical University Cancer Institute and Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a phase II prospective study to evaluate the safety and efficacy of Tislelizumab monotherapy or combined with lenvatinib as neoadjuvant therapy for resectable hepatocellular carcinoma.

Conditions

• Resectable Hepatocellular Carcinoma

Interventions

Type	Name	Description
DRUG	Tislelizumab	Tislelizumab 200mg, iv, d1, Q3W
DRUG	Tislelizumab, Lenvatinib	Tislelizumab combined with lenvatinib: Tislelizumab 200mg, iv, d1, Q3W Lenvatinib 8mg，po，qd.

Timeline

• Start date: 2023-04-24
• Primary completion: 2024-07-24
• Completion: 2025-07-31
• First posted: 2023-04-11
• Last updated: 2026-04-01

Locations

1 site across 1 country: China